Caspase-mediated pathways in retinal ganglion cell injury: a novel therapeutic target for glaucoma

Glaucoma is a complex disease of the optic nerve leading to vision loss and blindness, with high worldwide incidence and disproportionate prevalence in older populations. Primary open-angle glaucoma, caused by a reduction in outflow of aqueous humor through the trabecular meshwork, is the most commo...

Full description

Saved in:
Bibliographic Details
Main Authors: Nisha Rajakrishna, Seok Ting Lim, Xiaomeng Wang, Tina T. Wong
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2025.1586240/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850171575697932288
author Nisha Rajakrishna
Nisha Rajakrishna
Seok Ting Lim
Seok Ting Lim
Xiaomeng Wang
Xiaomeng Wang
Xiaomeng Wang
Tina T. Wong
Tina T. Wong
Tina T. Wong
author_facet Nisha Rajakrishna
Nisha Rajakrishna
Seok Ting Lim
Seok Ting Lim
Xiaomeng Wang
Xiaomeng Wang
Xiaomeng Wang
Tina T. Wong
Tina T. Wong
Tina T. Wong
author_sort Nisha Rajakrishna
collection DOAJ
description Glaucoma is a complex disease of the optic nerve leading to vision loss and blindness, with high worldwide incidence and disproportionate prevalence in older populations. Primary open-angle glaucoma, caused by a reduction in outflow of aqueous humor through the trabecular meshwork, is the most common subset of the disease, though its underlying molecular mechanisms are not well understood. While increased intraocular pressure is the most common risk factor in glaucoma progression, the disease is ultimately characterized by the loss of retinal ganglion cells (RGCs) and destruction of the optic nerve. Given the irreversibility of RGC death, neuroprotection of RGCs is a promising avenue of glaucoma prevention and treatment. The caspase family of proteins are integral members of the apoptotic death cascade. They have been shown to play a significant role in RGC death in numerous models of retinal injury. Direct inhibition of several caspase family members, through targeted siRNAs and peptidomimetics, demonstrate promising capacity to reduce caspase expression and preserve RGCs following intraocular pressure increase or optic injury. A wide variety of alternative therapeutics targeted for RGC survival, including neurotrophins, immunomodulators, cytoprotectants, and endogenous hormones, also display indirect caspase-inhibiting capabilities. Following intraocular pressure increase or external retinal injury, both direct and indirect caspase inhibitors elicit higher RGC counts, increased RGC layer thickness, and attenuation of RGC damage, clearly demonstrating the neuroprotective abilities of caspase inhibitors. Caspase inhibition, particularly by direct approaches of siRNA or peptidomimetic-based therapeutics, has the potential to achieve substantial neuroprotection in the glaucomatous eye.
format Article
id doaj-art-36f43883e7d24fdeb42abc8ebb009e2c
institution OA Journals
issn 2296-634X
language English
publishDate 2025-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cell and Developmental Biology
spelling doaj-art-36f43883e7d24fdeb42abc8ebb009e2c2025-08-20T02:20:15ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2025-04-011310.3389/fcell.2025.15862401586240Caspase-mediated pathways in retinal ganglion cell injury: a novel therapeutic target for glaucomaNisha Rajakrishna0Nisha Rajakrishna1Seok Ting Lim2Seok Ting Lim3Xiaomeng Wang4Xiaomeng Wang5Xiaomeng Wang6Tina T. Wong7Tina T. Wong8Tina T. Wong9Drug Delivery and Ocular Therapeutics, Singapore Eye Research Institute, Singapore, SingaporeCentre for Vision Research, Duke-NUS Medical School, Singapore, SingaporeDrug Delivery and Ocular Therapeutics, Singapore Eye Research Institute, Singapore, SingaporeCentre for Vision Research, Duke-NUS Medical School, Singapore, SingaporeDrug Delivery and Ocular Therapeutics, Singapore Eye Research Institute, Singapore, SingaporeCentre for Vision Research, Duke-NUS Medical School, Singapore, SingaporeInstitute of Molecular and Cell Biology, A*STAR, Singapore, SingaporeDrug Delivery and Ocular Therapeutics, Singapore Eye Research Institute, Singapore, SingaporeCentre for Vision Research, Duke-NUS Medical School, Singapore, SingaporeGlaucoma Department, Singapore National Eye Centre, Singapore, SingaporeGlaucoma is a complex disease of the optic nerve leading to vision loss and blindness, with high worldwide incidence and disproportionate prevalence in older populations. Primary open-angle glaucoma, caused by a reduction in outflow of aqueous humor through the trabecular meshwork, is the most common subset of the disease, though its underlying molecular mechanisms are not well understood. While increased intraocular pressure is the most common risk factor in glaucoma progression, the disease is ultimately characterized by the loss of retinal ganglion cells (RGCs) and destruction of the optic nerve. Given the irreversibility of RGC death, neuroprotection of RGCs is a promising avenue of glaucoma prevention and treatment. The caspase family of proteins are integral members of the apoptotic death cascade. They have been shown to play a significant role in RGC death in numerous models of retinal injury. Direct inhibition of several caspase family members, through targeted siRNAs and peptidomimetics, demonstrate promising capacity to reduce caspase expression and preserve RGCs following intraocular pressure increase or optic injury. A wide variety of alternative therapeutics targeted for RGC survival, including neurotrophins, immunomodulators, cytoprotectants, and endogenous hormones, also display indirect caspase-inhibiting capabilities. Following intraocular pressure increase or external retinal injury, both direct and indirect caspase inhibitors elicit higher RGC counts, increased RGC layer thickness, and attenuation of RGC damage, clearly demonstrating the neuroprotective abilities of caspase inhibitors. Caspase inhibition, particularly by direct approaches of siRNA or peptidomimetic-based therapeutics, has the potential to achieve substantial neuroprotection in the glaucomatous eye.https://www.frontiersin.org/articles/10.3389/fcell.2025.1586240/fullcaspaseretinal cell deathglaucomaneuroprotectionretinal ganglion celloptic nerve
spellingShingle Nisha Rajakrishna
Nisha Rajakrishna
Seok Ting Lim
Seok Ting Lim
Xiaomeng Wang
Xiaomeng Wang
Xiaomeng Wang
Tina T. Wong
Tina T. Wong
Tina T. Wong
Caspase-mediated pathways in retinal ganglion cell injury: a novel therapeutic target for glaucoma
Frontiers in Cell and Developmental Biology
caspase
retinal cell death
glaucoma
neuroprotection
retinal ganglion cell
optic nerve
title Caspase-mediated pathways in retinal ganglion cell injury: a novel therapeutic target for glaucoma
title_full Caspase-mediated pathways in retinal ganglion cell injury: a novel therapeutic target for glaucoma
title_fullStr Caspase-mediated pathways in retinal ganglion cell injury: a novel therapeutic target for glaucoma
title_full_unstemmed Caspase-mediated pathways in retinal ganglion cell injury: a novel therapeutic target for glaucoma
title_short Caspase-mediated pathways in retinal ganglion cell injury: a novel therapeutic target for glaucoma
title_sort caspase mediated pathways in retinal ganglion cell injury a novel therapeutic target for glaucoma
topic caspase
retinal cell death
glaucoma
neuroprotection
retinal ganglion cell
optic nerve
url https://www.frontiersin.org/articles/10.3389/fcell.2025.1586240/full
work_keys_str_mv AT nisharajakrishna caspasemediatedpathwaysinretinalganglioncellinjuryanoveltherapeutictargetforglaucoma
AT nisharajakrishna caspasemediatedpathwaysinretinalganglioncellinjuryanoveltherapeutictargetforglaucoma
AT seoktinglim caspasemediatedpathwaysinretinalganglioncellinjuryanoveltherapeutictargetforglaucoma
AT seoktinglim caspasemediatedpathwaysinretinalganglioncellinjuryanoveltherapeutictargetforglaucoma
AT xiaomengwang caspasemediatedpathwaysinretinalganglioncellinjuryanoveltherapeutictargetforglaucoma
AT xiaomengwang caspasemediatedpathwaysinretinalganglioncellinjuryanoveltherapeutictargetforglaucoma
AT xiaomengwang caspasemediatedpathwaysinretinalganglioncellinjuryanoveltherapeutictargetforglaucoma
AT tinatwong caspasemediatedpathwaysinretinalganglioncellinjuryanoveltherapeutictargetforglaucoma
AT tinatwong caspasemediatedpathwaysinretinalganglioncellinjuryanoveltherapeutictargetforglaucoma
AT tinatwong caspasemediatedpathwaysinretinalganglioncellinjuryanoveltherapeutictargetforglaucoma